Dr. Rob Meijers is the Head of Neuroscience at the Institute for Protein Innovation (IPI), a non-profit organization dedicated to advancing protein science and technology in Boston, United States. At IPI, he leads efforts to develop renewable recombinant antibodies by combining synthetic biotechnology with machine learning protocols. The goal is to produce and distribute well-validated affinity reagents to support the life sciences community. Dr. Meijers’ team focuses on creating antibody panels for neuroscience applications, enabling the study of synapse formation, axon guidance, and other neural processes that require novel protein tools. He also is as a part-time lecturer at Harvard Medical School.